Cilla Haywood Australian & New Zealand Obesity Society 2016 Annual Scientific Meeting

Abstracts this author is presenting:

• Improvement in SF-36-derived health utility score with liraglutide 3.0 mg versus placebo over 3 years in prediabetes — Mini Poster-Oral Session
• Liraglutide 3.0 mg in obese/overweight adults with or without prediabetes with baseline BMI <35 vs ≥35 kg/m² in the SCALE Obesity and Prediabetes 56-week randomized, double-blind, placebo-controlled trial — Lunch & Poster Session